<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880603</url>
  </required_header>
  <id_info>
    <org_study_id>Restrata</org_study_id>
    <nct_id>NCT04880603</nct_id>
  </id_info>
  <brief_title>Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site</brief_title>
  <official_title>Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nebraska Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acera Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nebraska Methodist Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients undergoing a radial forearm free flap or ulnar forearm free flap will be&#xD;
      randomized to the use of the Restrata graft in combination with split-thickness skin graft&#xD;
      for reconstruction. Photos will document whether the Restata graft aids in the healing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tendon exposure</measure>
    <time_frame>4 weeks post-operation</time_frame>
    <description>Tendon exposure at four weeks post-operatively (Yes/No).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of surface area</measure>
    <time_frame>4 weeks post operation</time_frame>
    <description>Percentage of surface area of split-thickness skin graft incorporation at four weeks postoperatively.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>A - Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Restrata Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restrata Graft</intervention_name>
    <description>Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.</description>
    <arm_group_label>B - Restrata Graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care Skin Graft</intervention_name>
    <description>Standard of Care Skin Graft</description>
    <arm_group_label>A - Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients age 19 or greater that will undergo radial forearm free flap or ulnar&#xD;
             free flap.&#xD;
&#xD;
          -  Photo documentation of wound bed at two weeks and four weeks must be obtainable either&#xD;
             by physician or patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active systemic immunosuppression (active use of high-dose steroids (≥40mg prednisone&#xD;
             daily or equivalent) or other immunosuppressive medications OR medical conditions&#xD;
             causing immunosuppression, i.e. human immunodeficiency virus etc).&#xD;
&#xD;
          -  Diabetes mellitus with most recent Hemoglobin A1c ≥10.0 within 30 days prior to&#xD;
             surgery.&#xD;
&#xD;
          -  Morbid obesity (BMI &gt;40).&#xD;
&#xD;
          -  Inability to maintain wrist immobilization for full planned period.&#xD;
&#xD;
          -  Severe malnutrition (prealbumin levels &lt;10 mg per dL within 30 days prior to surgery&#xD;
             OR BMI &lt;15 (very severely underweight).&#xD;
&#xD;
          -  Other conditions felt to significantly impair wound healing per surgeon discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lindau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nebraska Methodist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Bartz, RN</last_name>
    <phone>402-354-7939</phone>
    <email>kathryn.bartz@nmhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Bartz, RN</last_name>
      <phone>402-354-7939</phone>
    </contact>
    <investigator>
      <last_name>Robert Lindau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

